Research article · 2014
Research articlePublished 2014
Design, Synthesis and Calcium Channel Blocking Activity of Diltiazem- Verapamil Hybrid Molecules
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The current manuscript describes the design, synthesis, and in vitro testing of four thioacetanilides with diltiazemverapamil hybrid structural features as potential calcium channel blockers. The current hybrid strategy of drug design aimed to generate compounds that could span, with a single compound, the trans-membrane locales where the two drugs bind, with the ultimate goal of increasing the blocking activity. The latter, was assessed by measuring the inhibitory effects, expressed as IC50, on calcium-induced contractions of potassium depolarized isolated rat aorta strips. The assessment of the binding locales was determined by incubating the test compound with aortic strips for two different periods, 10-minutes and 2-hours, before adding the contractile calcium ions to the assay medium. Diltiazem IC50 values were 0.26 and 0.14 μM, after 10-minutes and 2-hours, respectively, reflecting less than two fold increase in activity and confirming previous reports that its locale of binding in mostly on the exterior side of the membrane. On the other hand, verapamil IC50 values were 0.47 and 0.14 μM after 10-minutes and 2-hour incubation respectively, reflecting approximately a 3-4 fold increase in activity and confirming previous reports that it binds mainly to the interior domains of the membrane. The four designed hybrid compounds showed, after 10-minute incubation, an IC50 value range of 3.7-12.0 μM, and after 2-hour incubation an IC50 range of 0.78-2.12 μM, reflecting approximately a 5-fold increase in activity suggesting more similarity to the verapamil binding profile. The data indicate that the designed compounds are with moderate activities, but generally less active as calcium channel blockers than either of the two parent drugs.
Keywords
Subjects
ChemistryPharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 27 Jul 2022
Computational drug design and synthesis of pharmacophore based hybrid oncological molecules
Conference abstract · 24 May 2022
Computational Drug design and synthesis of Pharmacophore based hybrid Oncological molecules
Research article · 28 Feb 2012
2DQSAR of novel 1,4-dihydropyridine derivative blocking n-type - calcium channels
Commentary · 31 Jan 2025
Design and Development of Hybrid Molecules Targeting Multi-drug Resistant Bacteria
More from this journal
The newest in Medicinal Chemistry.
Brief report · 30 Jun 2026
Covalent Drugs in Medicinal Chemistry: Emerging Opportunities and Ongoing Challenges
Commentary · 29 Dec 2025
Accelerating Drug Discovery: Molecular Docking and Virtual Screening
Opinion · 29 Dec 2025
Pharmacophore Modeling: A Cornerstone of Drug Discovery
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMedicinal Chemistry
- SubjectChemistry
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ahmed S Mehanna”
- BylineArticles whose byline prints “Timothy J Maher”
- BylineArticles whose byline prints “Pintapa P Grongsaard”

